Inivata Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
70
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$399M
- Investors
-
1
Inivata General Information
Description
Developer of medical tests designed to detect cancer using liquid biopsies. The company's platform focuses on harnessing the potential of circulating tumor DNA (ctDNA) analysis, monitoring response, and detecting relapse, thereby helping clinicians make informed treatment decisions with respect to the treatment of cancer patients.
Contact Information
Website
www.inivata.com(Operating Subsidiary)
Corporate Office
- Glenn Berge Building
- Babraham Research Campus, Babraham
- Cambridge CB22 3FH
- England, United Kingdom
Corporate Office
- Glenn Berge Building
- Babraham Research Campus, Babraham
- Cambridge CB22 3FH
- England, United Kingdom
Inivata Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 18-Jun-2021 | $399M | Completed | Generating Revenue | ||
| 7. Secondary Transaction - Private | 15-Mar-2021 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C) | 04-Feb-2021 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 03-Jun-2020 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 01-Apr-2019 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 26-Jan-2016 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 23-Sep-2014 | $6.55M | $6.55M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2014 | Completed | Startup |
Inivata Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C2 Preferred | ||||||||
| Series C2 Preferred | ||||||||
| Series C1 | ||||||||
| Series C1 | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series A | 16,591,575 | $0.000014 | 7% | $2.59 | $2.59 | $2.59 | 25.34% | |
| Preference | 4,000,000 | $0.000014 | 5% | $1.36 | $1.36 | $1.36 | 6.11% |
Inivata Comparisons
Industry
Financing
Details
Inivata Competitors (38)
One of Inivata’s 38 competitors is Boreal Genomics, a Formerly VC-backed company based in Vancouver, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Boreal Genomics | Formerly VC-backed | Vancouver, Canada | ||||
| ROCA Test | Formerly VC-backed | Cambridge, United Kingdom | ||||
| BioGenex Laboratories | Corporation | Fremont, CA | ||||
| Foundation Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Oxford Immunotec | Formerly VC-backed | Abingdon, United Kingdom |
Inivata Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Inivata Patents
Inivata Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250037792-A1 | Computational assessment of genetic variant quality | Pending | 25-Jul-2023 | ||
| US-20240425930-A1 | Methods for selective sequencing of cancer dna | Pending | 22-Jun-2023 | ||
| EP-4573219-A1 | Method of detecting cancer dna in a sample | Pending | 19-Aug-2022 | ||
| GB-202212094-D0 | Method of detecting cancer dna in a sample | Inactive | 19-Aug-2022 | ||
| AU-2021322806-A1 | Highly sensitive method for detecting cancer dna in a sample | Pending | 05-Aug-2020 | C12Q1/6886 |
Inivata Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Inivata Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cambridge Innovation Capital | Venture Capital | Minority | ||
| Cancer Research Horizons | Venture Capital | Minority | ||
| Farallon Capital Management | Hedge Fund | Minority | ||
| Future Planet Capital | Venture Capital | Minority | ||
| IP Group | Venture Capital | Minority |
Inivata FAQs
-
When was Inivata founded?
Inivata was founded in 2014.
-
Where is Inivata headquartered?
Inivata is headquartered in Cambridge, United Kingdom.
-
What is the size of Inivata?
Inivata has 70 total employees.
-
What industry is Inivata in?
Inivata’s primary industry is Diagnostic Equipment.
-
Is Inivata a private or public company?
Inivata is a Private company.
-
What is the current valuation of Inivata?
The current valuation of Inivata is .
-
What is Inivata’s current revenue?
The current revenue for Inivata is .
-
How much funding has Inivata raised over time?
Inivata has raised $164M.
-
Who are Inivata’s investors?
Cambridge Innovation Capital, Cancer Research Horizons, Farallon Capital Management, Future Planet Capital, and IP Group are 5 of 14 investors who have invested in Inivata.
-
Who are Inivata’s competitors?
Boreal Genomics, ROCA Test, BioGenex Laboratories, Foundation Medicine, and Oxford Immunotec are some of the 38 competitors of Inivata.
-
When was Inivata acquired?
Inivata was acquired on 18-Jun-2021.
-
Who acquired Inivata?
Inivata was acquired by NeoGenomics Laboratories.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
